In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids with Eric A. Adams, InMed’s CEO, and Alexandra Mancini, senior VP of clinical and regulatory affairs. The discussion also includes the recent FDA public hearing on cannabidiol (CBD) and its implications for the sector.
The Dales Report – InMed Pharmaceuticals Positioned For Growth As Cannabinoid Supply Sales Poised For Imminent “Take Off”
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, on the fast-growing synthesized cannabinoid industry and the market opportunity of rare cannabinoids.
September 22, 2021
